ABOUT THE BOARD OF DIRECTORS
number of directors set by the Board is nine. Currently, there are two vacancies on the Board, one vacancy in Class I and one
vacancy in Class II. Robert J. Messey, a Class III director, discussed with the Nominating and Corporate Governance Committee
of the Board his intent to retire from the Board in the next year. On the recommendation of the Committee, the Board nominated
Mr. Messey for election to the Board to fill the vacancy in Class I and serve a one-year term which, if approved, will create
a vacancy in Class III.
forth below is the name, age, and business experience of each of the continuing directors and nominees of the Company, including
the specific experience, qualifications, attributes or skills that led to the conclusion that such person should serve as a director.
Dr. Nathan Fischel is the father of David L. Fischel, our Chief Executive Officer and Chairman of the Board.
I Director (Nominee for election to the Board at the 2019 Annual Meeting to serve a one-year term until the 2020 Annual Meeting)
since May 2005
Messey, 73, served as the senior vice president and chief financial officer of Arch Coal, Inc. from December 2000 until his retirement
in April 2008. Prior to joining Arch Coal, he served as the vice president of financial services of Jacobs Engineering Group,
Inc. from 1999 to 2000 following that company’s acquisition of Sverdrup Corporation, where he served as senior vice president
and chief financial officer from 1992 to 1999. Mr. Messey was an audit partner at Ernst & Young LLP from 1981 to 1992. He
previously served as a director and member of the audit and compensation committees of Oxford Resource Partners, LP, a publicly
traded coal mining company, from May 2010 to December 2014, and as a director and chairman of the audit committee of Baldor Electric
Company, a publicly traded manufacturer of industrial electrical motors, from May 1993 to January 2011. He serves as an advisory
director, chairman of the audit committee, and member of the compensation committee of a privately held mining company. Mr. Messey
earned his B.S.B.A. from Washington University. Mr. Messey’s experience in finance and accounting provides the Board with
a great deal of expertise on financing, accounting and compliance matters.
III Directors (terms expiring at the 2019 Annual Meeting; Nominees for election to the Board at the 2019 Annual Meeting to serve
a three-year term until the 2022 Annual Meeting)
since February 2017
Fischel, 63, is
the Founder and CEO of DAFNA Capital Management, LLC. DAFNA Capital is
an SEC registered investment advisor with a highly successful investment track record
of over 18 years focused on innovations in biotechnology and medical devices. Dr. Fischel was Professor of Pediatrics at
UCLA School of Medicine, and attending physician in Pediatric Hematology and Oncology at
Cedars-Sinai Medical Center in Los Angeles.
He has published over 120 peer-reviewed scientific and medical manuscripts and book chapters, has been the principal investigator
of multiple National Institutes of Health (“NIH”) funded research grants,
has served repeatedly on internal and external review panels at the NIH, and was appointed by the U.S. Secretary of Health
and Human Services to serve for four years on the Advisory Council of
one of the NIH’s institutes. Dr. Fischel received his M.D. from the Technion Israel Institute of Technology and
served his internship year at Hadassah Hospital in Jerusalem.
He completed his residency and fellowship in Pediatrics and Pediatric Hematology and Oncology at the Children’s Hospital
and the Dana-Farber Cancer Institute, Harvard Medical School in
Boston, and his postgraduate research training in Molecular Genetics at Oxford
University in England. Dr. Fischel’s
experience as a physician enables him to provide critical perspectives regarding our technologies and commercial adoption of our
products and his extensive knowledge of medical device companies allows him to provide insight to the Board on strategic decisions.